Ajay Shah is currently the Director of Research Informatics at Elan Pharmaceuticals. Prior to Elan, he was Associate Director of Chemistry Informatics, heading the Compound Design Center of Excellence at Pfizer, La Jolla. Prior to Pfizer, he held various scientific programming and post-sales support positions at Accelrys, a scientific software company. Ajay has a Ph.D. in Chemistry from the University of Mississippi, did his post-doctoral research at the University of Arizona and has an Executive MBA from the Eller School of Management at the University of Arizona.

Dr. Brown is presently VP and CSO for Acclerys. He has an impressive background in the Pharmaceutical industry in the field of Computational Science and Informatics. He has spent the last 20 years of his career innovating new scientific methods and applying them in commercial pharmaceutical enterprises. From 1997 to 2006, Dr. Brown held positions of increasing responsibility at Johnson & Johnson, one of the world?s largest Pharmaceutical companies, and, most recently, was a Senior Research Fellow within the Office of the CIO. Dr. Brown received his Ph.D. in Physical Organic Chemistry from the University of Pitts\ burgh under the direction of Ken Houk and did post doctoral studies in Biophysics at the University of California, San Francisco under the direction of Peter Kollman. He currently serves as an Adjunct Associate Professor at the University of North Carolina, Chapel Hill?s School of Pharmacy - Division of Medicinal Chemistry where he lectures on Molecular Modeling and Drug Design. Dr. Brown is a recognized industry expert having published over 50 peer-reviewed papers, delivered over 50 invited lectures, and is the named holder of two patents. He has been actively involved with a number of both scientific journals and profess\ ional magazines and has served on a number of associated editorial boards. Additionally, Dr. Brown has served on the funding committee for the National Institute of Heath and is the past Chairman of American Chemical Society?s ?Computers in Chemistry?. He is also recognized as the person who first defined Chemoinformatics and coined the word.

LTC Nhan Do holds a Medical Doctorate from the George Washington University and is board certified in Internal Medicine. He completed his residency at Madigan Army Medical Center (MAMC) and later held the positions of Consult Service Chief and Assistant Clinic Chief. At MAMC, he developed an interest in informatics and was a co-investigator on several eHealth research projects. After receiving his Masters of Science degree in Biomedical Informatics at Stanford University, he took a position of Medical Informaticist at Tricare Management Activity in Falls Church, Virginia. Currently he is involved in several projects in the Information Management Directorate at Tricare Management Activity to include health data standards, VA-DOD data sharing, and personal health record.

David serves as Chief Scientific Officer for BBC?s newly-created Target Generation Unit. This new unit brings together human genetics, systems biology, and cell biology, combining internal capabilities with outside collaborations, to focus on increasing preclinical target validation with the aim of significantly improving clinical survival. David is a co-founder of Perlegen, and was most recently Chief Scientific Officer of the company since its formation in 2000.

David was Professor of Genetics and Pediatrics at the Stanford University School of Medicine as well as the co-director of the Stanford Genome Center. He obtained his A.B. and M.S. degrees from Brown University in Rhode Island and his M.D. and Ph.D. degrees from the University of Washington, Seattle. He completed a Pediatric Residency at the Yale-New Haven Hospital in New Haven, Connecticut and was a Fellow in both genetics and pediatrics at the University of California, San Francisco.

David is certified by the American Board of Pediatrics and the American Board of Medical Genetics. He was an active participant in the large scale mapping and sequencing efforts of the Human Genome Project while carrying out research involving the molecular basis of human genetic disease.

David has been a member of several commissions and boards, including the National Bioethics Advisory Commission (NBAC) and the Health Sciences Policy Board of the Institute of Medicine. He has also served on a number of international committees, including the Council of the Human Genome Organization (HUGO). He has authored over 100 peer-reviewed scientific publications and has served on numerous editorial boards.

Dr. Cox?s honors include election to the Institute of Medicine of the National Academy of Sciences.

Vikram Mohan is currently the Director of Product Management at BioImagene, Inc. Vikram joined BioImagene four and a half years ago, and has held various positions at the company. Vikram has a B.S in Computer Science and an M.S. in Biomedical Informatics, both from Stanford University.

Dr. Schadt joined Rosetta in November 1999 where he founded bioinformatics and computational genomics groups to mine large scale sets of data aimed at experimentally annotating the human genome. After Rosetta was acquired by Merck, Dr. Schadt formed a genetics/systems biology department within the Molecular Profiling Department at Merck, in which the primary mission is elucidating common human diseases and drug response using novel integrative genomics approaches based on genetic and molecular profiling data. His research has helped revolutionize a field in statistical genetics (the genetics of gene expression), has \ energized the systems biology field, and has led to a number of discoveries relating to the causes of common human diseases. As of the end of 2008, greater than 50% of all new drug discovery programs at Merck in the metabolic space were derived from Dr. Schadt's work. Dr. Schadt also holds an affiliate professor position in the Department of Biostatistics at the University of Washington in Seattle, and he was recently appointed as Fellow to the Institute of Systems and Synthetic Biology, Imperial College London. Prior to joining Rosetta/Merck, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his\ B.S. in applied mathematics/computer science from California Polytechnic State University, his M.A. in pure mathematics from UCD, and his Ph.D. in bio-mathematics from UCLA (requiring Ph.D. candidacy in molecular biology and mathematics).